



New Hampshire Department of Health and Human Services

Substance Use Disorder Treatment and Recovery Access Section 1115(a) Research and Demonstration Waiver

Annual Post Award Forum - MCAC

October 18, 2021

Agenda

- **Overview**
- **Timeline of Significant Actions**
- **Serious Mental Illness (SMI) Amendment Overview**
- **Timeline of Future Deliverables Next Steps**
- **Next Steps**
- **Questions**

Overview

The New Hampshire Department of Health and Human Services requested a Substance Use Disorder Treatment and Recovery Access Section 1115(a) Demonstration Waiver to allow New Hampshire to provide Medicaid payments for individuals receiving substance use disorder (SUD) services in an Institution for Mental Disease (IMD). This request will further the objectives of Title XIX by increasing access to residential SUD treatment services for adults and adolescents in New Hampshire.

Specifically, New Hampshire requested that:

- 1) CMS waive Section 1905(a)(29)(B), 42 CFR 438.6(e), and 42 CFR 435.1010 to allow a waiver of the IMD exclusion for Medicaid-eligible individuals aged 21 to 64 receiving residential substance use disorder (SUD) treatment in an IMD for as long as is medically necessary.
- 2) CMS expand the exception to the IMD exclusion in 42 CFR 441.11(c)(5) to the provider type Comprehensive SUD program, as described in He-W 513.02 (b) to allow New Hampshire to claim federal financial participation (FFP) for individuals under 21 receiving residential substance use disorder treatment in these facilities for long as is medically necessary.

Timeline of Significant Actions

July 10, 2018

- Demonstration Approved
- FFP for expenditures began
- SUD Implementation Protocol approved

April 2019

- Initial Evaluation Plan Design submitted to CMS

May 2019

- Final Evaluation Plan submitted to and approved by CMS

August 2020

- Budget Neutrality Amendment submitted to prospectively adjust budget neutrality target

March 2021

- PHCG selected as evaluator for Mid-Point Assessment and Evaluation Plan

June 2021

- CMS approved Budget Neutrality Amendment and sent revised STC's

September 2021

- Serious Mental Illness (SMI) Amendment to the demonstration waiver submitted

SMI Amendment Overview

As part of its overall approach to addressing the increase in Emergency Department boarding and to support the comprehensive, integrated continuum of mental health treatments and care available in the state, DHHS is applying for an amendment to its Section 1115(a) Demonstration from CMS

- This amendment will enable DHHS to claim federal reimbursement for payment of services provided to Medicaid beneficiaries ages 21-64 receiving short-term inpatient psychiatric treatment or short-term residential mental health treatment in an Institution for Mental Disease (IMD).
- The services proposed within this amendment include those that are in alignment with the existing mental health delivery system for inpatient psychiatric and residential mental health treatment and are not intended to reduce or replace services provided in less restrictive settings.

Timeline of Future Deliverables

2021

- Mid-Point Assessment due by December 31, 2021
- Regular quarterly monitoring reports, annual report, and annual post-award forum

2022

- SMI Amendment implementation targeted for July 1, 2022, pending CMS approval
- Regular quarterly monitoring reports, annual report, and annual post-award forum
- Draft Interim Evaluation report in June
- Submit request to renew and extend demonstration including aligning the SMI amendment with overall SUD demonstration

Timeline of Future Deliverables

2023

- Draft Close-out Operational Report in March
- SUD demonstration waiver and the SMI waiver end June 30, 2023
- Regular quarterly monitoring reports, annual report, and annual post-award forum

2024

- Draft Summative Evaluation Report due in December

2025

- Final Evaluation due in March

Next Steps

- Respond to Mid-Point Assessment findings
- Prepare for SMI Amendment implementation pending CMS approval
- On going data collection and analysis of the Prescription Drug Monitoring Program (PDMP)

Questions and Answers